StockData

Myriad Genetics vs Neogen

MYGN and NEOG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MYGN and NEOG compare

Neogen is the larger company, worth 4.5 times as much as Myriad Genetics ($2.4B against $533M).

Neogen grew revenue faster over the last twelve months (−0.33% versus −3.2% for Myriad Genetics).

Neogen keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −14.0% at Myriad Genetics.

Neogen scores higher on the StockData Score (7 against 6 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMYGNNEOG
Size and price
Market cap$533M$2.4B
Share price$5.57$10.88
Change, 1 year−12.3%70.8%
Change, 5 years−79.1%−73.6%
Beta (5Y)−0.100.86
Employees2,7002,636
StockData Score
Total score67 (better)
Valuation score11
Growth score02 (better)
Performance score33
Health score2 (better)1
Dividend score00
Valuation
P/S0.7× (better)2.7×
P/B1.8×1.1× (better)
EV/EBITDA–34.5×
P/FCF–47.7×
FCF yield–2.1%
Fair value–$7.30
Margin of safety–−49.0%
Growth
Revenue growth (TTM)−3.2%−0.33% (better)
Revenue growth, 5Y average−0.63%13.2% (better)
Profitability
Gross margin68.8% (better)47.4%
Operating margin−12.2%−0.83% (better)
Net margin−14.0%−6.3% (better)
FCF margin–5.6%
Return on equity−32.5%−2.7% (better)
Return on invested capital−22.8%−0.17% (better)
Financial health
Debt / equity0.40 (better)0.74
Net debt / EBITDA–12.69
Interest coverage−6.0×–
Current ratio2.213.90 (better)
Altman Z-score−0.621.35 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.1%109%
Held by insiders7.2%0.60%
Insider net buying, 12 months$655K (better)−$102K
Short interest, % of float9.5%5.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.